Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IV Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
Conditions
Brief summary
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the objective response rate (complete and partial response), as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria, in patients with advanced refractory biliary cancers (BC) receiving Akt inhibitor MK2206 (MK2206). SECONDARY OBJECTIVES: I. To determine the frequency and severity of adverse events and tolerability of the regimen in patients with advanced refractory BC receiving MK2206. II. To determine the overall and progression-free survival of patients with advanced refractory BC receiving MK2206. III. To determine the presence of genetic mutations of PI3-kinase/ Akt pathway signaling-pathway genes relevant to BC and how these correlate with objective response to treatment with MK2206. IV. To determine the pharmacokinetic and pharmacogenetic profile as a way of assessing inter-individual variability as well as how these relate to clinical outcomes. V. To determine genetic variants and mutations in genes encoding drug-metabolizing enzymes and transporters, and genes involved in tumor biology, and how these may be related to response to treatment. OUTLINE: This is a multicenter study. Patients receive Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and periodically during study for pharmacokinetic, pharmacogenetic, and other correlative studies. Previously collected tumor tissue is also analyzed. After completion of study therapy, patients are followed up for 4 weeks.
Interventions
DRUGAkt Inhibitor MK2206
Given PO
OTHERDiagnostic Laboratory Biomarker Analysis
Correlative studies
OTHERPharmacological Study
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed biliary tract carcinoma that is surgically unresectable * Cytological confirmation is not allowed on this study, as tissue is needed for correlative science analysis * Either fresh-frozen tissue (FFT) or paraffin-embedded tissue blocks (PETB) will be required from patients before enrolling on this study * No biopsies will be required unless there is insufficient tissue or if the PETB available is more than 12 months old * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with spiral CT scan (CT scan slice thickness no greater than 5 mm) * Malignant lymph nodes will be considered measurable if they are ≥ 15 mm in short axis * Patients must have received one prior therapy for metastatic disease * No prior Akt inhibitors allowed * Patients with known brain metastases should be excluded from this clinical trial * Life expectancy greater than 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\<2 (Karnofsky \>= 60%) * Leukocytes \>= 3,000/mcL * Absolute neutrophil count (ANC) \>= 1,500/mcL * Platelet count \>= 100,000/mcL * Total bilirubin =\< 1.5 x institutional upper limit of normal (IULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\] =\< 2.5 x IULN * Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal (measured or calculated using the Cockroft-Gualt formula) * Women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation * Not pregnant or nursing * Able to swallow oral tablets * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to Akt Inhibitor MK2206 (MK2206) or other agents used in the study * Patients with diabetes or in risk for hyperglycemia should not be excluded from trials with MK2206, but the hyperglycemia should be well controlled on oral agents before the patient enters the trial * Cardiovascular: baseline QTcF \> 450 msec (male) or QTcF \> 470 msec (female) will exclude patients from entry on study * Patients with clinically significant bundle branch block or pre-existing clinically significant bradycardia will be excluded from the study * No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements * No concurrent grapefruit or grapefruit juice * For patients having prior cryotherapy, radiofrequency ablation, ethanol injection, transarterial chemoembolization (TACE), or photodynamic therapy, the following criteria must be met: * 6 weeks has elapsed since that therapy * Indicator lesion(s) is/are outside the area of prior treatment or, if the only indicator lesion is inside the prior treatment area, there must be clear evidence of disease progression associated with that lesion * Edges of the indicator lesion are clearly distinct on CT scanning * Prior radiation therapy with or without the use of a fluoropyrimidine as a radiosensitizer in the adjuvant setting will be allowed on study if \> 12 weeks have elapsed since therapy * Prior palliative radiation therapy will allowed as long as \> 4 weeks have elapsed since therapy * No patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Patients may not be receiving any other investigational agents * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible * Patients receiving any medications or substances that are inhibitors or inducers of CYP 450 3A4 are ineligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1 | Up to 4 weeks after completion of study treatment, for total treatment time of up to 1 year | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Adverse Events Related to MK-2206 | Up to 4 weeks after completion of study treatment, for total treatment time of up to 1 year | Severity of adverse events is graded according to the NCI CTCAE 4.0. |
| Overall Survival | From study initiation to time of death, assessed up to 4 weeks after completion of study treatment | Analyzed using Kaplan-Meier method. |
| Progression-free Survival | From start of treatment to time of documented progression or death whichever occurs first, assessed up to 4 weeks after completion of study treatment | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
Countries
United States
Participant flow
Recruitment details
Patients were enrolled between September 2012 and December 2013
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Akt Inhibitor MK2206) Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Akt Inhibitor MK2206: Given PO
Diagnostic Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies | 8 |
| Total | 8 |
Baseline characteristics
| Characteristic | Treatment (Akt Inhibitor MK2206) |
|---|---|
| Age, Continuous | 58 years |
| Disease site Extrahepatic | 2 patients |
| Disease site Gallbladder | 0 patients |
| Disease site Intrahepatic | 6 patients |
| ECOG Performance Status PS 0 | 2 patients |
| ECOG Performance Status PS 1 | 6 patients |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 7 Participants |
| Region of Enrollment United States | 8 patients |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 8 / 8 |
| serious Total, serious adverse events | 0 / 8 |
Outcome results
Primary
Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 4 weeks after completion of study treatment, for total treatment time of up to 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Akt Inhibitor MK2206) | Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1 | 0 patients |
Secondary
Frequency of Adverse Events Related to MK-2206
Severity of adverse events is graded according to the NCI CTCAE 4.0.
Time frame: Up to 4 weeks after completion of study treatment, for total treatment time of up to 1 year
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Akt Inhibitor MK2206) | Frequency of Adverse Events Related to MK-2206 | lymphopenia | 75 percentage of patients |
| Treatment (Akt Inhibitor MK2206) | Frequency of Adverse Events Related to MK-2206 | rash | 63 percentage of patients |
| Treatment (Akt Inhibitor MK2206) | Frequency of Adverse Events Related to MK-2206 | fatigue | 50 percentage of patients |
| Treatment (Akt Inhibitor MK2206) | Frequency of Adverse Events Related to MK-2206 | fever | 50 percentage of patients |
| Treatment (Akt Inhibitor MK2206) | Frequency of Adverse Events Related to MK-2206 | vomiting | 50 percentage of patients |
| Treatment (Akt Inhibitor MK2206) | Frequency of Adverse Events Related to MK-2206 | diarrhea | 50 percentage of patients |
Secondary
Overall Survival
Analyzed using Kaplan-Meier method.
Time frame: From study initiation to time of death, assessed up to 4 weeks after completion of study treatment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Akt Inhibitor MK2206) | Overall Survival | 3.5 months |
Secondary
Progression-free Survival
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: From start of treatment to time of documented progression or death whichever occurs first, assessed up to 4 weeks after completion of study treatment
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Treatment (Akt Inhibitor MK2206) | Progression-free Survival | 1.7 months |